Eyetelligence Assure Clinical Decision Support Software
PRODUCT VIDEO
Eyetelligence Assure • Developed to support clinical decision making
• AI technology analyse retinal
images for features of glaucoma, referrable diabetic retinopathy, and neovascular AMD
• works with any standard retinal camera, connected to a PC
4
How was the AI trained? • AI-based deep learning model
trained & validated using data set of more than 200.000 images
• dataset assessed & labelled by subspecialist ophthalmologists
• Label is consensus of three panellists • Software assigns label based on the culmination of this learning
• Peer reviewed & published
5
Better results for everyone
§ § §
User-friendly traffic light system Easy to explain to customers Shows clients & staff you are investing in a tool to support them
§
§
Generates revenue by qualifying need for appropriate tests (VFT, OCT)
§
Reports worth business;
§
§
Clinical reports easy for referring GPs
Makes existing equipment work harder
§
Improves referrals & standardizes disease screening process
§
Customer reports to support your recommendations, increase client understanding
Offline solution - total confidentiality
§
6
Helps you and your clients § Drives customer engagement with screening for their eye health
§ Visual tool that shows customers you invest in the latest technology
§ Increases your revenue by realizing all possible in-clinic testing opportunities
7
How does it works?
Install Eyetelligence Assure on a PC connected to fundus camera and take the client’s retinal photos
The images will appear in the software interface. Choose the images you want analysed
Receive analysis within seconds for features of glaucoma, referrable DR or n-AMD.
Check the results section for a list of the day’s clients and results
Click to view and download your clinical report or client report, both complete with your logo.
8
Glaucoma decision support § Glaucoma detection is challenging - even for a specialist
§ Allows you to select and prioritise which clients really require visual field testing
9
Diabetic Retinopathy screening support with grading § Follows RANZCO Screening and Referral Pathway
§ Allows clinicians to determine if the patient needs further monitoring or referral
§ AI report indicates the level of confidence by the following grades*: • • • • •
No DR Mild non-proliferative DR (NPDR) Moderate NPDR Severe NPDR Proliferative DR
Fundus Grading Report Patient Name
Age
Sex
Date and time
Patient D
61
Male
2021-06-09 12:17:48
Right eye Results (OD)
Disease type
Left eye Results (OS)
Status
Disease type
Status
Glaucoma:
Low risk, 98% CL
Glaucoma:
Diabetic Retinopathy:
Severe NPDR, 58% CL
Diabetic Retinopathy:
Severe NPDR, 98% CL
Neovascular Age-related Macular
Negative, 98% CL
Neovascular Age-related Macular
Negative, 100% CL
Degeneration:
Low risk, 100% CL
Degeneration:
Please note that Eyetelligence Assure generates the above results based solely on the retinal photo, without referring to any additional medical information. Any grading result displayed in this report should be used to support clinical decision making, and shall not replace professional medical advice, diagnosis or treatment. Glaucoma: Glaucoma disc suspect de ned as VCDR >= 0.7 or rim width <= 0.1 with or without RNFL defect or disc haemorrhage DR: Classi ed as No DR, Mild, Moderate and Severe NPDR and Proliferative DR according to International Council of Ophthalmology guidelines Disclaimer: It is important to note that the software algorithm results may be misled by artifacts. These artifacts may include re ection from the inner limiting membrane typically seen among people less than 40 years old. AMD: Neovascular AMD de ned as serous detachment of sensory retina or RPE, or sub-RPE retinal haemorrhage or sub-retinal/sub-RPE brovascular proliferation or disciform scar CL = Con dence Level, the percentage of all possible samples that can be expected to include the true population parameter.
*DR application is intended for use in people over the age of 40
Regulatory Disclaimer The Eyetelligence software is approved for clinical use in European Union, the UK, Australia and New Zealand by relevant authorities as a Class I medical device. It is intended for providing initial classi cation on the full colour retinal images collected from fundus camera for the existence and severity of three speci c eye diseases. It does not intend to
10
replace clinical judgements from healthcare professionals. Eyetelligence software outcomes/recommendations should be reviewed in consideration of other inputs by appropriate quali ed clinicians for making diagnostic and referral decisions.
Referrable nAMD screening support
§ Trained to recognise the features of nAMD
§ The results are displayed as either green (no nAMD present) or red (nAMD is present).
§ Screening for features of early, intermediate AMD and geographic atrophy AMD in development
11
Reports § Build client loyalty § Support your recommendations
Fundus Grading Report Patient Name
Age
Sex
Date and time
Patient D
61
Male
2021-06-09 12:17:48
Right eye Results (OD)
Left eye Results (OS)
§ Generate revenue
Clinical Report §
§
§
Viewed on both the capture PC and on a PC connected Results with descriptions & confidence level (where a high % means a higher confidence of a correct grading) Makes it easy for time-poor GPs, encourages them to send you more patients
Disease type
Status
Disease type
Status
Glaucoma:
Low risk, 98% CL
Glaucoma:
Low risk, 100% CL
Diabetic Retinopathy:
Severe NPDR, 58% CL
Diabetic Retinopathy:
Severe NPDR, 98% CL
Neovascular Age-related Macular
Negative, 98% CL
Neovascular Age-related Macular
Negative, 100% CL
Degeneration:
Degeneration:
Please note that Eyetelligence Assure generates the above results based solely on the retinal photo, without referring to any additional medical information. Any grading result displayed in this report should be used to support clinical decision making, and shall not replace professional medical advice, diagnosis or treatment. Glaucoma: Glaucoma disc suspect de ned as VCDR >= 0.7 or rim width <= 0.1 with or without RNFL defect or disc haemorrhage DR: Classi ed as No DR, Mild, Moderate and Severe NPDR and Proliferative DR according to International Council of Ophthalmology guidelines Disclaimer: It is important to note that the software algorithm results may be misled by artifacts. These artifacts may include re ection from the inner limiting membrane typically seen among people less than 40 years old. AMD: Neovascular AMD de ned as serous detachment of sensory retina or RPE, or sub-RPE retinal haemorrhage or sub-retinal/sub-RPE brovascular proliferation or disciform scar CL = Con dence Level, the percentage of all possible samples that can be expected to include the true population parameter.
Regulatory Disclaimer The Eyetelligence software is approved for clinical use in European Union, the UK, Australia and New Zealand by relevant authorities as a Class I medical device. It is intended for providing initial classi cation on the full colour retinal images collected from fundus camera for the existence and severity of three speci c eye diseases. It does not intend to replace clinical judgements from healthcare professionals. Eyetelligence software outcomes/recommendations should be reviewed in consideration of other inputs by appropriate quali ed clinicians for making diagnostic and referral decisions.
12
Reports Retinal Image Analysis
§ Build patient loyalty § Support your recommendations § Generate revenue
Patient Name
Age
Sex
Date and time
Patient D
61
Male
2021-06-09 12:17:48
Your retinal photographs have been analysed, using Eyetelligence arti cial intelligence software, for features of three common sight-threatening diseases: glaucoma, diabetic retinopathy and late wet age-related macular degeneration. Your optometrist will use the Eyetelligence assessment as part of an overall comprehensive eye examination. This report does not constitute a clinical diagnosis. The approved use for this application is for use in people over the age of 40, results for patients under 40 years of age should be interpreted with caution. Contact your optometrist if you have any questions or concerns.
Client Report §
Build client loyalty with take-home report to share with family
§
Supports your recommendations and reminds of follow-up appointments
§
§
Option to charge or offer as a valueadd customer experience
Your analysis
Disease type
Right eye
Left eye
Glaucoma
Low risk
Low risk
Diabetic Retinopathy
Severe NPDR
Severe NPDR
Late Wet AMD
Negative
Negative
Includes your logo
13
International approvals Partners with world-leading research organisations, multiple international regulatory approvals
14
Optometrist feedback
Help patients understand the need for additional tests ü
Informs the patient of the diseases being tested for and provides support to justify the reason for retinal images
ü
Easy-to-understand results are reassuring for patients
Clinical and patient reports, complete with your logo
Helpful. Even if you already have OCT
ü “I feel patients would want ü In practice with OCT, it’s to have a general screening worth using as indicator for report, so that’s a really good OCT scan option”, Kris ü “If it makes us check again, ü Adds value and the odd case, then it's understanding to patient worth it, and in a practice experience with no OCT its almost double the value.” Selwyn ü Patient report shows what they are paying for with additional testing
Added assurance
ü “It’s that extra bit of assurance, the extra attention to cupping and optic nerve” Pam ü “As a recent graduate it really helps to confirm those borderline cases”, Lauren
15
Optometrist Feedback ”It’s a good tool for patients to see the progression of their disease, and the percentage levels are comforting to the patients that provide certainty.” Barry Clennar
"It’s really seamless and easy to use, and the report comes out straight away. It’s extra data that I didn’t have before. And the more information is good. I’ve liked using it.” Richard Shaw “I find it justifies the cost of retinal photos through the extra information it provides. And it justifies the need for further testing, especially in higher risk cases.” Barry Clennar We have found value with it in testing for glaucoma, and the new update has improved the DR screening. Laura
“It’s been really helpful with starting out as a recent graduate. I found it good with borderline cases where Eyetelligence can help confirm or deny these cases. Lauren Henderson “It’s a good software and it decreases the chance of missing glaucoma and DR. And it’s a good software as a screening tool for retinal photos, that might be missed.” Jack Ma “It adds more to the OCT, and the patient report sounds like a good upgrade. I think patients want to have a general screening…so it’s a good option.” Kris “I think the overall opinion from the optometrists was positive and can see the value of having the software in stores.” Sarah Park
Testimonials “It justifies the cost of retinal photos through the extra information it provides” -Barry “It’s like a safety net for a lot of our optometrists to pick up on tiny details that may or may not necessarily pick up just from a fundus image alone” – Sarah “The percentages provide an estimate indication to how I will recall my patients and for OCTs”- Alivia Now that I’ve got this information, especially for glaucoma suspect because it’s such a grey area, and now I’ve got a percentage interval…I wouldn’t go back now that I have it in my arsenal”- Richard
“The value of having the program is regular referrals from GPs...it would potentially drive more referrals in the future as the GP will have something on file for the patient” - Jessy “I found 2 cases that were flagged by Eyetelligence; one was thinning on the rim and the other a suspicious cup. And we underwent field tests as a result” - Margaret “Adds that extra justification for why you're doing these billable tests so yes very positive” - Pam “It provides testing if there is a need to do an OCT, and that’s valuable as we charge for OCT separately a flat fee” - Selwyn
17
All prices in Euros. By downloading Eyetelligence Software you agree to our Privacy Policy and Terms & Conditions.
EYETELLIGENCE EUROPE +31-653 991 800 www.eyetelligence-assure.com Netherlands